Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02556372 · ClinicalTrials.gov registry record · Phase 2
Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies
A Phase 2 study of Autoimmune Hepatitis, sponsored by TaiwanJ Pharmaceuticals Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 16
- Study locations
NCT02556372 is a Phase 2 study of Autoimmune Hepatitis that has completed, run by TaiwanJ Pharmaceuticals Co.. The registered enrollment target is 20 participants, below the 224-participant average among 5 other Autoimmune Hepatitis trials with a reported enrollment target (91% lower). The trial reports 16 study locations across 10 states.
The verdict
NCT02556372, a Phase 2 study of Autoimmune Hepatitis, has completed, sponsored by TaiwanJ Pharmaceuticals Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is a Phase 2, pilot study in which JKB-122 is given once daily for 24 weeks in subjects with autoimmune hepatitis (AIH) who have liver enzymes that are 1.25 to 10 times the upper limit of normal (ULN) and who have had a failed response to, incomplete response to, intolerant to, ineligible to, or unwilling to take current immunosuppressant therapies. The dose of JKB-122 will be escalated monthly.
Conditions Studied
Interventions
- DRUG JKB-122
Study Locations (16)
Texas
- Methodist Dallas Medical Center - Dallas
- Advanced Liver Therapies, Baylor College of Medicine - Houston
- The Texas Liver Institute - San Antonio
- Taxes Liver Institute - San Antonio
California
- Ruane Clinical Research Group, Inc. - Los Angeles
- University of California Davis Medical Center - Ticon 1 - Sacramento
- California Pacific Medical Center - San Francisco
Washington
- Swedish Medical Center - Organ Transplant and Liver Center - Seattle
- University of Washington - Seattle
Florida
- University of Florida Hepatology Research at CTRB - Gainesville
Illinois
- Northwestern University - Chicago
Indiana
- Indiana University School of Medicine - Indianapolis
Louisiana
- Tulane University - New Orleans
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-04-30 |
| Est. Completion | 2019-01-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02556372
The ClinicalTrials.gov registry entry for NCT02556372 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 224-participant average among 5 other Autoimmune Hepatitis trials with a reported enrollment target (91% lower). The listed sponsor is TaiwanJ Pharmaceuticals Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autoimmune Hepatitis appearing as the primary indexed condition, and to 1 intervention - of which JKB-122 is the first listed.
NCT02556372 reports 16 study locations spanning 10 distinct geographic areas - top geographies include Texas, California, Washington.
Frequently Asked Questions
What is clinical trial NCT02556372 about?
NCT02556372 is a clinical study titled "Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies". This is a Phase 2, pilot study in which JKB-122 is given once daily for 24 weeks in subjects with autoimmune hepatitis (AIH) who have liver enzymes that are 1.25 to 10 times the upper limit of normal (ULN) and who have had a failed response to, incomplete response to, intolerant to, ineligible to, o...
What is the current status of trial NCT02556372?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-04-30. Estimated completion is 2019-01-21.
What conditions does trial NCT02556372 study?
This clinical trial studies the following conditions: Autoimmune Hepatitis.
What interventions are being tested in trial NCT02556372?
The interventions under investigation include: JKB-122 (DRUG).
Who is sponsoring clinical trial NCT02556372?
This trial is sponsored by TaiwanJ Pharmaceuticals Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02556372 being conducted?
This trial has 16 study locations across California, Florida, Illinois, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autoimmune Hepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
RECRUITING
-
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
RECRUITING
-
A-LiNK: Improving Outcomes in Autoimmune Liver Disease
RECRUITING
-
Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis Patients
RECRUITING · NA
-
A Study of SIPLIZUMAB in AILD and LT Patients
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.